Pantozol Control

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

pantoprazole

Disponible depuis:

Takeda GmbH

Code ATC:

A02BC02

DCI (Dénomination commune internationale):

pantoprazole

Groupe thérapeutique:

Proton pump inhibitors

Domaine thérapeutique:

Gastroesophageal Reflux

indications thérapeutiques:

Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults.

Descriptif du produit:

Revision: 17

Statut de autorisation:

Authorised

Date de l'autorisation:

2009-06-11

Notice patient

                                22
B. PACKAGE LEAFLET
23
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
PANTOZOL CONTROL 20 MG GASTRO-RESISTANT TABLETS
pantoprazole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist have told
you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
-
You must talk to a doctor if you do not feel better or if you feel
worse after 2 weeks.
-
You should not take PANTOZOL Control tablets for more than 4 weeks
without consulting a
doctor.
WHAT IS IN THIS LEAFLET
1.
What PANTOZOL Control is and what it is used for
2.
What you need to know before you take PANTOZOL Control
3.
How to take PANTOZOL Control
4.
Possible side effects
5.
How to store PANTOZOL Control
6.
Contents of the pack and other information
1.
WHAT PANTOZOL CONTROL IS AND WHAT IT IS USED FOR
PANTOZOL Control contains the active substance pantoprazole, which
blocks the ‘pump’ that
produces stomach acid. Hence it reduces the amount of acid in your
stomach.
PANTOZOL Control is used for the short-term treatment of reflux
symptoms (for example heartburn,
acid regurgitation) in adults.
Reflux is the backflow of acid from the stomach into the gullet
(“foodpipe”), which may become
inflamed and painful. This may cause you symptoms such as a painful
burning sensation in the chest
rising up to the throat (heartburn) and a sour taste in the mouth
(acid regurgitation).
You may experience relief from your acid reflux and heartburn symptoms
after just one day of
treatment with PANTOZOL Control, but this medicine is not meant to
bring immediate relief. It may
be necessary to take the tablets for 2-3 consecutive days to relieve
the symptoms.
_ _
You must talk to a doctor if you do not feel bet
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
PANTOZOL Control 20 mg gastro-resistant tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 20 mg pantoprazole (as sodium
sesquihydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Gastro-resistant tablet.
Yellow, oval, biconvex film-coated tablets imprinted with “P20” in
brown ink on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
PANTOZOL Control is indicated for short-term treatment of reflux
symptoms (e.g. heartburn, acid
regurgitation) in adults.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended dose is 20 mg pantoprazole (one tablet) per day.
It might be necessary to take the tablets for 2-3 consecutive days to
achieve improvement of
symptoms. Once complete relief of symptoms has occurred, treatment
should be discontinued.
The treatment should not exceed 4 weeks without consulting a doctor.
If no symptom relief is obtained within 2 weeks of continuous
treatment, the patient should be
instructed to consult a doctor.
Special populations
No dose adjustment is necessary in elderly patients or in those with
impaired renal or liver function.
_ _
_Paediatric population _
_ _
PANTOZOL Control is not recommended for use in children and
adolescents below 18 years of age
due to insufficient data on safety and efficacy.
Method of administration
PANTOZOL Control 20 mg gastro-resistant tablets should not be chewed
or crushed, and should be
swallowed whole with liquid before a meal.
3
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.
Co-administration of pantoprazole is not recommended with HIV protease
inhibitors for which
absorption is dependent on acidic intragastric pH such as atazanavir,
nelfinavir; due to significant
reduction in their bioavailability (see section 4.5).
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Patients should be instructed to consult a doctor if:
•
Th
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 02-05-2013
Notice patient Notice patient espagnol 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 02-05-2013
Notice patient Notice patient tchèque 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 02-05-2013
Notice patient Notice patient danois 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation danois 02-05-2013
Notice patient Notice patient allemand 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 02-05-2013
Notice patient Notice patient estonien 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 02-05-2013
Notice patient Notice patient grec 25-05-2023
Notice patient Notice patient français 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation français 02-05-2013
Notice patient Notice patient italien 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation italien 02-05-2013
Notice patient Notice patient letton 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation letton 02-05-2013
Notice patient Notice patient lituanien 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation lituanien 02-05-2013
Notice patient Notice patient hongrois 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 02-05-2013
Notice patient Notice patient maltais 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 02-05-2013
Notice patient Notice patient néerlandais 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 02-05-2013
Notice patient Notice patient polonais 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 02-05-2013
Notice patient Notice patient portugais 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 02-05-2013
Notice patient Notice patient roumain 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 02-05-2013
Notice patient Notice patient slovaque 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 02-05-2013
Notice patient Notice patient slovène 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 02-05-2013
Notice patient Notice patient finnois 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 02-05-2013
Notice patient Notice patient suédois 25-05-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 02-05-2013
Notice patient Notice patient norvégien 25-05-2023
Notice patient Notice patient islandais 25-05-2023
Notice patient Notice patient croate 25-05-2023

Rechercher des alertes liées à ce produit

Afficher l'historique des documents